

JOINT WARFIGHTER MEDICAL RESEARCH PROGRAM

Program History

The Joint Warfighter Medical Research Program (JWMRP) provides the Department of Defense (DOD) with a powerful tool for advancing previously funded Congressional Special Interest and core program funded medical research and development projects that address military medical requirements of the Services while complementing and enhancing the Defense Medical Research and Development Program (DMRDP). The JWMRP leverages the efforts of industry and academia for projects that show promise in closing identified military medical capability gaps and provides the funding to move these products through the developmental process.

Each year, a broad spectrum of research projects are considered for funding under the JWMRP. The projects align to the six Joint Program Committees (JPCs) scientific domains represented in the DMRDP, including Medical Simulation and Information Sciences, Military Infectious Diseases, Military Operational Medicine, Combat Casualty Care, Radiation Health Effects, and Clinical and Rehabilitative Medicine.

Congress first appropriated \$50 million (M) for the JWMRP in fiscal year 2012 (FY12) and again in FY13; later doubling the appropriation to \$100M in FY14, followed by \$50M per fiscal year in FY15-FY19 and \$40M in FY20. Because the overall goal of the program is to deliver a product for the DOD, the proportion of funding available for advanced technology development initiatives has been adapted over the years. A total of 28 projects were funded by the JWMRP in FY12, 35 in FY13, 46 in FY14, 30 in FY15, 34 in FY16, 27 in FY17, 17 in FY18 and 13 in FY19. The graph below depicts the program investments for FY19.

The JWMRP is a dynamic program that facilitates maturation of previous Congressionally and core programmed funded efforts that demonstrate the potential to close identified military medical capability gaps. By focusing on both early and advanced technology development, the JWMRP provides a pathway to transition products to military healthcare providers and the Warfighter.


Vision: Move military relevant medical solutions forward in the acquisition life-cycle to meet the needs of Service members and other military health system beneficiaries

Mission: Accelerate research and development projects that have the potential to close high priority Department of Defense medical capability gaps


“JWMRP has been vital in supporting the Navy to accelerate a multiple prototype strategy for bacteriophage. Armata Pharmaceuticals - the selected award recipient - will continue to validate the potential for phage-based therapeutics with a second clinical program testing a targeted phage cocktail to treat *Staphylococcus aureus* bacteremia.”

Mr. Thomas Dunn, Navy Advanced Development Representative, Navy Medical Research Center

Congressionally Directed Medical Research Programs



FY19 JWMRP Investment
(% of total FY19 Investment)



FY19 JWMRP Final Funding Distribution
(Number of Awards Granted Indicated in Each Bar Chart)



Research and Product Development Efforts Funded by the JWMPR Include:

Technology Readiness Level

4

Focused effort on improving cognitive and functional deficits in individuals with traumatic brain injury (TBI) using virtual technology

Accelerating development of freeze dried plasma in a combat ready rugged lightweight container



Development of an implantable pudendal nerve stimulator to restore bladder function in humans after spinal cord injury

Investigational New Drug-enablement of Kinocidin Gamma-RP-1 for multidrug-resistant gram-negative infections

Development of BIO301 as an oral prophylactic and post-exposure treatment for acute radiation syndrome

Development of a thermoresponsive reversible adhesive for temporary intervention of ocular trauma

Treatment of adult severe TBI using autologous bone marrow mononuclear cells

Phase III clinical trial of Peripheral Nerve Stimulation System for improving functional outcomes by alleviating pain in individuals with major lower limb amputations



Development of a novel product for temporary corneal repair

5

Development of a lyophilized injectable for a point-of-care therapeutic for post-traumatic osteoarthritis

Phase I/II clinical trial of Bacteriophage for Treatment of Bacterial Infections

Phase I clinical trial for a direct acting polymyxin antibiotic to treat multidrug resistant gram-negative pathogens

Phase II/III clinical trial of Riluzole for spinal cord injury

6

Development of a moisture management liner and active cooling system for lower limb prostheses to improve fit, comfort, and residual limb skin care

7

Device development of the Transportable Pathogen Reduction and Blood Safety System

Development of a non-electric, disposable intravenous infusion pump

<https://cdmrp.army.mil/jwmp/>

Point of Contact: CDMRP Public Affairs, 301-619-9783

usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

DoD visual images are for illustrative purposes only. Some images were cropped to emphasize subject matter.